Journal article
Authors list: Tarner, I. H.; Mueller-Ladner, U.; Hamm, C.
Publication year: 2010
Pages: 702-70+
Journal: Zeitschrift für Rheumatologie
Volume number: 69
Issue number: 8
ISSN: 0340-1855
eISSN: 1435-1250
DOI Link: https://doi.org/10.1007/s00393-009-0583-7
Publisher: Springer
Abstract:
Over the course of the last decade, biologic response modifiers (biologics) have significantly broadened the therapeutic armamentarium in clinical rheumatology. In addition to their impressive efficacy, they have also received considerable attention regarding their adverse effects. In contrast to the risk of severe infections and malignancies, the cardiovascular risk of these drugs has provoked less vigilance. This article reviews the current data on the cardiovascular effects and adverse effects of biologics.
Citation Styles
Harvard Citation style: Tarner, I., Mueller-Ladner, U. and Hamm, C. (2010) Biologics and cardiovascular risk, Zeitschrift für Rheumatologie, 69(8), pp. 702-70+. https://doi.org/10.1007/s00393-009-0583-7
APA Citation style: Tarner, I., Mueller-Ladner, U., & Hamm, C. (2010). Biologics and cardiovascular risk. Zeitschrift für Rheumatologie. 69(8), 702-70+. https://doi.org/10.1007/s00393-009-0583-7
Keywords
ADVANCED HEART-FAILURE; ANTI-TNF THERAPY; Biologics; cardiovascular risk; Congestive heart failure; DOUBLE-BLIND; ETANERCEPT; FACTOR-ALPHA THERAPY; IMPROVES ENDOTHELIAL FUNCTION; INTERLEUKIN-6 RECEPTOR INHIBITION; RHEUMATOID-ARTHRITIS PATIENTS; TOCILIZUMAB
